MarketLens
Sign Up

What Did Legend Biotech's Investor Event Reveal About CARVYKTI

4 months ago
SHARE THIS ON:

What Did Legend Biotech's Investor Event Reveal About CARVYKTI

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 week ago

Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

Legend Biotech reported CARVYKTI data showing 50% of RRMM patients remained progression-free and alive five years after a single infusion, with a 69.2% five-year overall survival rate. The results add...
Stock News•2 weeks ago

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

Legend Biotech appointed Ingrid Zhang as CEO effective September 15, 2026, replacing the prior leadership. The board decision puts a new executive in charge of the cell therapy company's strategy and ...
Stock News•2 months ago

Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?

BMY filed for FDA approval of mezigdomide in relapsed/refractory multiple myeloma, advancing its CELMoD protein degrader pipeline.

Breaking News

View All →

Top Headlines

View More →
Stock News•1 hour ago

Microsoft (MSFT) Exceeds Market Returns: Some Facts to Consider

Stock News•1 hour ago

Nvidia (NVDA) Outperforms Broader Market: What You Need to Know

Stock News•1 hour ago

Tesla (TSLA) Laps the Stock Market: Here's Why

Stock News•1 hour ago

If you'd bought $10,000 worth of Amazon stock 10 years ago, here's how much you'd have today

Stock News•1 hour ago

Tesla Reports Quarterly Production and Delivery Figures. Here's What It Means for Investors